Objective:
The article summarizes Oculis CEO Riad Sherif’s remarks on privosegtor, reported phase 2 ACUITY results, and the status of the PIONEER phase 3 program.
Approach:
- Phase 2 evidence: Sherif said privosegtor improved vision by 18 letters compared with steroids alone in the phase 2 ACUITY trial, and reported preservation or improvement of retinal anatomy and reduced neurofilament release.
- Phase 3 program: Sherif said PIONEER-1, a study in optic neuritis, had started randomizing patients; PIONEER-2 was starting, and PIONEER-3 was planned to start afterward.
Key Findings:
- Sherif described privosegtor as a neuroprotective candidate.
- Sherif reported that ACUITY showed an 18-letter vision improvement compared with steroids alone, preservation or improvement of retinal anatomy, and reduced neurofilament release.
Interpretation:
Sherif said PIONEER-1 had started randomizing patients, PIONEER-2 was starting, and PIONEER-3 would start afterward; PIONEER-1 is a study in optic neuritis.
Limitations:
- The source is a company CEO’s conference statement, not a full clinical study report.
- The context provides no detailed trial methods, participant numbers, statistical analyses, or phase 3 results.
Conclusion:
Sherif described the PIONEER program as a long-term commitment to neuro-ophthalmology and an effort to build a neuroprotective franchise, starting with optic neuritis.
Sources:
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.